Evidence map›Paper›PMID 32661670›Full record

ArticleHead and neck pathology2021

The Utility of MYB Immunohistochemistry (IHC) in Fine Needle Aspiration (FNA) Diagnosis of Adenoid Cystic Carcinoma (AdCC).

Tong Sun, Ali Akalin, Karen Dresser, Andrew H Fischer, Tao Zuo

Open access · hybridAbstract read
In one paragraph

Article in Head and neck pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. A Study on Myloblastosis Gene (MYB) in Adenoid Cystic Carcinoma Using the New IHC Marker MYB (SZ04-81).Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2023
    Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Tong SunDepartment of Pathology, University of Massachusetts Medical School, Worcester, MA, 01655, USA. tong.sun@mgh.harvard.edu.ORCID http://orcid.org/0000-0003-3399-1202
Ali AkalinDepartment of Pathology, University of Massachusetts Medical School, Worcester, MA, 01655, USA.
Karen DresserDepartment of Pathology, University of Massachusetts Medical School, Worcester, MA, 01655, USA.
Andrew H FischerDepartment of Pathology, University of Massachusetts Medical School, Worcester, MA, 01655, USA.
Tao ZuoDepartment of Pathology, University of Massachusetts Medical School, Worcester, MA, 01655, USA. tao.zuo@umassmemorial.org.
University of Massachusetts Chan Medical School · USBoston University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Differentiating adenoid cystic carcinoma (AdCC) from other basaloid neoplasm in a fine needle aspiration (FNA) sample can be challenging. Activation of MYB in AdCC by the fusion transcript MYB-NFIB has been recently demonstrated in salivary gland and other organs. The aim of this study is to evaluate the utility of MYB immunohistochemistry (IHC) in distinguishing AdCCs and other basaloid neoplasm in cytology specimens. Eighteen FNA cases, from salivary gland and other sites, and their subsequent surgical resection specimens were included in the study. Eight cases were confirmed AdCC on resection. MYB IHC was performed on slides made from cytology cell block and surgical resection paraffin blocks. Percentage and intensity of nuclear staining in tumor cells was scored as 0 to 3. The staining results were concordant between cytology specimens and their corresponding surgical resection tumors. Strong diffuse nuclear staining (score 3, N = 5) was exclusively observed in AdCC, both in cytology and surgical specimens. Only one pleomorphic adenoma and one poorly differentiated basaloid carcinoma were positive for MYB staining (score 1 to 2). Any degree of nuclear MYB labeling was seen in 100% AdCC cases (N = 8/8) compared with of 20% (N = 2/10) of all other non-AdCC cases (P = < 0.001). The sensitivity and specificity of any degree MYB positivity for AdCC in cytology specimen is 100% and 78%. The sensitivity and specificity of strong diffuse MYB labeling (score 2 to 3) for AdCC is 83% and 100% in cytology specimen. Strong diffuse nuclear staining of MYB is valuable in supporting a cytologic diagnosis of AdCC. However, weak and focal labeling of MYB should be interpreted with caution as it can be seen in benign and other malignant basaloid lesions.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorBiopsy, Fine-NeedleCarcinoma, Adenoid CysticFemaleHumansImmunohistochemistryMaleMiddle AgedProto-Oncogene Proteins c-mybBiomarkers, TumorMYB protein, humanProto-Oncogene Proteins c-mybAdenoid cystic carcinomaFine needle aspirationImmunohistochemistryMYB

Identifiers

PMID32661670
PMCPMC8134651
OpenAlexW3040861752

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.